|
All are welcomed to participate in the Stakeholder Survey concerning a Potential USP Public Standard on Mutagenic Impurities
|
|
0
|
112
|
April 2, 2026
|
|
Question on the Method for Determining the Maximum Allowable Daily Usage of Terbinafine Ointment and Solution Formulations
|
|
2
|
150
|
April 2, 2026
|
|
đ¸đŹ Singapore formalized Nitrosamine requirements for NDA and GDA Applications
|
|
0
|
126
|
April 1, 2026
|
|
FDA Announcement - Small Molecule Nitrosamines in Infusion Bags
|
|
17
|
2744
|
March 31, 2026
|
|
N-nitroso-Furosemide
|
|
2
|
492
|
March 31, 2026
|
|
Analysis method of cream
|
|
6
|
261
|
March 30, 2026
|
|
Determination of N-nitroso Caspofungin
|
|
1
|
112
|
March 27, 2026
|
|
Excipient Nitrosamine Risk Assessment Tool
|
|
1
|
512
|
March 26, 2026
|
|
Nitrosamine formation in differnt dosage forms
|
|
10
|
399
|
March 24, 2026
|
|
Optimized UHPLCâDerivatization Method for Low-Level Nitrite Detection in Pharmaceutical Excipients-Pub
|
|
0
|
203
|
March 23, 2026
|
|
Impact of post approval quantitative changes in excipient composition on nitrosamine formation: De-risking strategy-Pub
|
|
0
|
129
|
March 23, 2026
|
|
đ¨âđť Determination of nitrite and nitrate in Microcrystalline Cellulose by ion chromatography
|
|
0
|
196
|
March 23, 2026
|
|
How to Validate High-Resolution Mass Spectrometry for Nitrosamine Detection in Pharmaceuticals
|
|
3
|
357
|
March 21, 2026
|
|
N-Nitrosoatorvastatin and applicable potency category 4 or 5
|
|
2
|
120
|
March 20, 2026
|
|
Mutagenicity of EAT-positive NDSRIs in HepaRG spheroids-Pub
|
|
0
|
70
|
March 20, 2026
|
|
Minimizing in Source Fragmentation for Mass Spectrometry Based NDSRI Analytical Procedures: A Case Study of Nitroso-bumetanide -Pub
|
|
4
|
315
|
March 19, 2026
|
|
Request for analytical method support â N-nitroso-piperidine in LVP elastomeric packaging (E&L study)
|
|
0
|
125
|
March 19, 2026
|
|
Physical form of nitrosamine Standards
|
|
1
|
128
|
March 18, 2026
|
|
Differences in Physical Form of Nitrosamine Reference Standards: USP vs. Other Suppliers
|
|
2
|
159
|
March 18, 2026
|
|
Scientific Clarification Request on Analytical Approach for Nitrosamine Determination in Quetiapine Oral Suspension
|
|
3
|
235
|
March 17, 2026
|
|
Research on Nitrosamines in Complex Preparations
|
|
2
|
190
|
March 17, 2026
|
|
MEGLUMINE (Methylglucamine)
|
|
28
|
3766
|
March 16, 2026
|
|
EMA Q&A Appendix 1 update posted on 13 March 2026
|
|
1
|
445
|
March 16, 2026
|
|
Challenges in developing an analytical method for Nânitrosoâambroxol -
|
|
1
|
147
|
March 14, 2026
|
|
Testing of N-nitroso-cinacalcet
|
|
8
|
1036
|
March 14, 2026
|
|
Limit Test for NDSRI Risk Assessment?
|
|
3
|
187
|
March 13, 2026
|
|
Navigating the complexities in characterization of NDSRIs using advanced analytical techniques-Pub
|
|
2
|
239
|
March 12, 2026
|
|
Challenges in developing an analytical method for Nânitrosoâambroxol
|
|
3
|
217
|
March 11, 2026
|
|
Register for Free Webinar- Australia and New Zealand: Nitrosamines Impurities 19 March 2026
|
|
0
|
217
|
March 10, 2026
|
|
Register for Quality Hour- Japan Edition: Nitrosamines Impurities 18 March 2026
|
|
0
|
221
|
March 8, 2026
|